Peter Marcus Kristensen

TL;DR: This chapter describes two types of plasminogen activators—namely, the urokinase-type plasMinogen activator (u-PA) and the tissue- type plasmineg activator(t-PA), which are essentially different gene products.

TL;DR: The results indicate that GHS have other effects on neuroendocrine regulation than GH release via GHRH neurons, and Stimulation of the arcuate NPY neurons via GHS-R may explain the increased appetite and the cortisol release seen after administration of some GHS compounds.

TL;DR: The present data support a role for CART in neuroendocrine regulation, co-stored with neurotransmitters having both positive (melanin-concentrating hormone) and negative effect on food intake and energy balance.

TL;DR: It is demonstrated that the plasminogen activator present in endothelium of veins and other blood vessels is of the tissue‐type, which supports the assumption that mobilization of plAsmin for different purposes may involve different types of plasmineogen activators, and that thePlasminagen activator involved in thrombolysis is ofThe tissue‐ type.

TL;DR: Mouse monoclonal antibodies derived against a plasminogen activator inhibitor derived from cultured human umbilical cord endothelial cells identified four clones of hybridomas producing IgG1 antibodies which could be used for immunocytochemical localization of the inhibitor in HT-1080 cells.